Cellectis S.A. Advances UCART123 Clinical Study in AML Treatment

Cellectis S.A. ((CLLS)), Cellectis SA ((CMVLF)) announced an update on their ongoing clinical study.

In a recent update, Cellectis S.A. has provided new insights into their ongoing clinical study titled ‘Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia.’ This study aims to assess the safety and clinical activity of UCART123v1.2, a Universal Chimeric Antigen Receptor T-cell targeting CD123, in patients with relapsed or refractory acute myeloid leukemia (AML). The primary goal is to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

The intervention being tested is UCART123v1.2, an allogeneic engineered T-cell therapy expressing an anti-CD123 chimeric antigen receptor. This biological treatment is designed to target and eliminate cancer cells in AML patients.

The study follows an interventional design with a single-group assignment. It is an open-label trial, meaning there is no masking, and its primary purpose is treatment. The study is currently in Phase I, focusing on dose escalation and expansion to establish the MTD and RP2D.

Key dates for this study include its start date on June 19, 2017, and a recent update on August 4, 2025. These dates are crucial as they mark the timeline of the study’s progress and the latest developments.

The update on this study could influence Cellectis S.A.’s stock performance positively, as advancements in clinical trials often boost investor confidence. However, the competitive landscape in the biotech industry, particularly in AML treatments, remains intense, which could moderate market reactions.

The study is ongoing, with further details available on the ClinicalTrials portal.